Abstract
The microbiome has increasingly been linked to cancer. Little is known about the lung and oral cavity microbiomes in smokers, and even less for electronic cigarette (EC) users, compared to never-smokers.
In a cross-sectional study (n=28) of smokers, EC users, and never-smokers, bronchoalveolar lavage and saliva samples underwent metatranscriptome profiling to examine associations with lung and oral microbiomes. Pairwise comparisons assessed differentially-abundant bacteria species.
Total bacterial load was similar between groups, with no differences in bacterial diversity across lung microbiomes. In lungs, 44 bacteria species differed significantly (FDR<0.1) between smokers/never-smokers, with most decreased in smokers. Twelve species differed between smokers/EC users, all decreased in smokers of which Neisseria sp. KEM232 and Curvibacter sp. AEP1–3 were observed. Among the top 5 decreased species in both comparisons, Neisseria elongata, Neisseria sicca, and Haemophilus parainfluenzae were observed. In the oral microbiome, 152 species were differentially abundant for smokers/never-smokers, and 17 between smokers/electronic cigarette users, but only 21 species were differentially abundant in both the lung and oral cavity.
EC use is not associated with changes in the lung microbiome compared to never smokers, indicating EC toxicity does not affect microbiota. Statistically different bacteria in smokers compared to EC users and never-smokers were almost all decreased, potentially due to toxic effects of cigarette smoke. The low numbers of overlapping oral and lung microbes suggest that the oral microbiome is not a surrogate for analyzing smoking-related effects in the lung.
Keywords: Microbiome, RNA-sequencing, Metatranscriptome, E Cigarettes, Cigarette, Lung microbiome, Oral microbiome
Prevention Relevance:
The microbiome affects cancer and other disease risk. The effects of e-cig usage on the lung microbiome are essentially unknown. Given the importance of lung microbiome dysbiosis populated by oral species which have been observed to drive lung cancer progression, it’s important to study effects of e-cig use on microbiome.
Introduction
Smoking causes at least 18 different types of cancer and numerous other diseases [1]. Electronic cigarettes (EC) have been purported to be a less harmful alternative nicotine delivery device for adult smokers who completely switch to ECs, although there are substantial concerns regarding an adverse impact on youth uptake [2, 3]. Even though EC use has been associated with substantially lower exposure to cigarette smoke toxicants [4, 5]. EC use has been hypothesized to have similar and also unique toxic effects compared to smoking, including an inflammation effect [6, 7]. Understanding the effects of EC use on target organs including the lung and oral cavity is critically important.
There is a growing interest on the relationship of the human microbiome with carcinogenesis and other diseases [8, 9]. Microbial dysbiosis (altered relative abundance of bacteria within bacterial communities – number and diversity of species) and increases in specific bacteria genera/species are hallmarks of numerous diseases, including lung disease and lung cancer [10–13]. How microbial dysbiosis might affect lung disease and cancer risk is currently poorly understood, but hypothesized to occur through alterations in inflammation pathways [14–18].
Smoking has been well-demonstrated to affect the oral microbiome [18–20], which are reversable with smoking cessation [21, 22]. There are associations with changes in the oral microbiome affecting lung cancer and lung disease risk [13, 23]. Many of the same oral microbiota have been reported as present in the lung [24, 25]. It is hypothesized that oral microbiota migrate into the lung through microaspiration, and also via inhalation and dispersion along the mucosa [26–28]. However, the relative abundance of bacteria may differ between the oral cavity and lung [25]. Several studies indicated an impact of EC use on the oral cavity microbiome, but the impact of EC use has not been studied in the human lung [29–32].
We hypothesized that smoking cigarettes and EC use impact the lung and oral microbiome in similar ways. Accordingly, we conducted a microbial metatranscriptome study in the oral cavity and lung of 28 individuals to seek associations with smokers (SM) compared with never-smokers (NS), and for the first time report associations with EC use. Also compared to earlier studies of SM/NS, we used metatranscriptome RNA sequencing (RNA-sequencing) that allows for bacterial identification to the species level and detects live bacteria [33].
Materials and Methods
Study participants:
A cross-sectional study of 28 healthy participants, age 21–30, was conducted from 2015–2017 (Table 1). The participants were a subset of a larger study previously described chosen to balance gender, age and sample availability [34]. There were 10 NS, 10 EC users (8 were former SM), and 8 SM. Using the CDC guidelines of smoking, NS were classified as smoking fewer than 100 cigarettes in their lifetime [35] and not have smoked a single cigarette or used EC for at least 1 year. EC users were defined as those who reported daily and frequent EC use for ≥ 6 months and had not smoked a single cigarette for at least 6 months. SM were defined as those smoking ≥100 cigarettes in their lifetime, have been smoking at least 5 cigarettes per day and for at least 6 months, and had not used ECs within one year.
Table 1.
Clinical Characteristics of Study Participants.
| NS (n=10) | EC (n=10) | SM (n=8) | P-value (Chi-square) | |
|---|---|---|---|---|
| Age (range) | 21–30 | 21–29 | 21–30 | 0.22 |
| Mean (±SD) | 25.6 (2.8) | 27.5 (1.9) | 25.9 (2.7) | |
| Gender | 0.38 | |||
| Male (%) | 6 (60%) | 6 (60%) | 7 (87.5%) | |
| Female (%) | 4 (40%) | 4 (40%) | 1 (12.5%) | |
| Race | 0.41 | |||
| White (%) | 8 (80%) | 8 (80%) | 8 (100%) | |
| African American / Asian (%) | 2 (20%) | 2 (20%) | 0 (0%) | |
| Bronchoscopy Site | 0.84 | |||
| Left Lung (%) | 5 (50%) | 5 (50%) | 5 (62.5%) | |
| Right Lung (%) | 5 (50%) | 5 (50%) | 3 (37.5%) | |
| Library Generation Batch | 0.89 | |||
| First Batch (%) | 6 (60%) | 6 (60%) | 4 (50%) | |
| Second Batch (%) | 4 (40%) | 4 (40%) | 4 (50%) | |
| Smoking | ||||
| Former (%) | 0 (0%) | 8 (80%) | 0 (0%) | |
| Current (%) | 0 (0%) | 0 (0%) | 8 (100%) | |
| Never (%) | 10 (100%) | 2 (20%) | 0 (0%) | |
| Years of smoking, average (range) | - | 4.3 (0–15)a | 7.9 (0.3–13) | 0.21 |
| Cigarettes per day, average (range) | - | 9.1 (0–20)a | 18.1 (10–20) | 0.18 |
| Years since last cigarettes, average (range) | - | 3.8 (0.5–10)a | 0 (0 – 0) | |
| E-cig Use | ||||
| Puffs per day, average (range) | - | 147.5 (80–500) | - | |
| E-liquid (mL/day), average (range) | - | 7.1 (2 −15) | - | |
| Nicotine (mg/mL), average (range) | - | 13.4 (3–36) | - |
former smoker e-cig users
This study was approved by the Ohio State University (OSU) Comprehensive Cancer Center Clinical Scientific Research Committee and the OSU Institutional Review Board.
Biospecimen collection:
Participants underwent bronchoscopy at the OSU Research Center after an orientation visit and consent. Bronchoalveolar lavage (BAL) was performed with 5–6 sequential 20 ml aliquots of saline. Aspirated samples were collected at each aliquot, combined and transported to lab on ice. Samples were promptly aliquoted into six 1 mL aliquots, within 30 minutes of BAL sample collection and immediately spun at 10,000g. The BAL supernatant was then removed, and the cell pellets for RNA-sequencing were resuspended in 1 mL of QIAgen RNAprotect cell reagent and stored at −80°C. To prepare for saliva collection, study participants were asked to refrain from brushing their teeth or chewing gum at least 90 minutes before their visit. Saliva samples were collected by having study participants spit into a 50 ml conical tube. The conical tube was then transported to lab on ice and the saliva transferred to a 15 ml conical tube with QIAGEN RNAprotect reagent. Samples were then promptly stored at −80°C.
RNA extraction and sequencing:
RNA from saliva and BAL cell pellets were extracted using miRNeasy kit (Qiagen, Germantown, MD). After extraction, RNA concentration was measured using Nanodrop spectrophotometer (Thermo Scientific, Walthman, MA) and Qubit fluorimeter (Life Technologies, Carlsbad, CA). RNA concentrations ranged from 4 to 267.8 (ng/μl) when measured by Nanodrop, and 4.4 to 280 (ng/μl) when measured by Qubit (Supplemental Table 1). All samples were prepped for library generation.
Adequate RNA integrity was determined using the Bioanalyzer (Agilent, Santa Clara, CA). Total RNA was then treated with TruSeq Stranded Total RNA Gold (Illumina, San Diego, CA) to remove rRNA; cDNA was then synthesized from the remaining total RNA and the library was generated. Final concentration measurements were measured using Qubit, and concentrations ranged from 0.27 to 10.8 (ng/μl). RNA-sequencing was done on the Illumina Hi-seq 4000 at 2 × 150 bps. Samples were sequenced to at least 35 million total reads per sample. Two saliva samples failed to produce enough total sequenced reads due to low concentration and could not produce minimum reads required. BaseSpace was used to demultiplexed reads, which produced read 1 and read 2 FASTQ files for each participant.
Data processing:
FASTQC was applied to FASTQ files to assess quality of reads. Reads with PHRED quality scores >=30 were retained. Cutadapt [36] was applied to trim adapter sequence. The remaining reads were then aligned to the human genome (Hg19) by TopHat [37] version (v.) 2.1.0, using the following parameters: -p 8 --no-coverage-search --library-type fr-firststrand hg19.genome Read1.fastq.gz Read2.fastq.gz.
Reads that were not mapped to the human genome were aligned to complete genomes of microbes downloaded from the NCBI RefSeq database (https://ftp.ncbi.nlm.nih.gov/genomes/refseq/) (dated March 2018). Kraken v.1 [38] was used for alignment with the following with the following parameters: kraken --preload –Kraken_Database --fastq-input --gzip-compressed --paired Microbiome_Read1.fastq.gz Microbiome_Read2.fastq.gz --output Microbial_alignment. Resulting alignment files were then converted into a read count table: kraken-report -Kraken_Database Microbial_alignment.
Aligned reads by Kraken were then provided to Bracken v.1 to align to bacterial species using the following parameters: python est_abundance.py -i BAL_Samples_Full_Kraken_subanalysis -k KMER_DISTR.txt. Bracken [39] was used because Kraken may classify some microbial reads to genus level or higher level taxonomic classification. Bracken re-classified all non-species classifications from Kraken to species level classifications. All bacterial counts were used to assess outlier subjects by principal component analysis (PCA). One lung sample was identified as an outlier from the PCA plot and removed. (Analysis by including the one outlier did not appreciably affect the results.)
Alpha and Beta Diversity Analysis:
Raw counts from Bracken alignment were used to calculate bacterial diversity. Alpha diversity (including number of observed species, Shannon Diversity Index and Gini-Simpson Index) was calculated using microbiome v. 1.9.1 [40] in R v. 3.5.3 using the alpha function. Beta diversity was calculated using vegan v.2.5–6 [41] vegdist function with the Bray-Curtis dissimilarity index. PERMANOVA from the adonis2 function of vegan was applied to the vegdist results and 1000 permutations were run to determine significance of beta diversity. Alpha diversity was compared using Kruskal-Wallis test, and beta diversity was compared using PERMANOVA.
Preprocessing and normalization:
Bacteria species were retained if they met the following two criteria: 1) species present in at least 2 study participants, and 2) aligned reads of that species is ≥ 0.005% total aligned microbial reads in a study participant. After filtering, in the oral microbiome, 763 bacteria species were retained out of 3345 and in the lung microbiome, 1016 bacteria species were retained out of 3073. After preprocessing, remaining reads were assessed for batch effects (library generation, extraction batch) and possible outliers subjects by PCA plot.
Remaining bacteria were normalized to library size using the calcNormFactor function in the edgeR package v.3.26.8 [42]. Log2-counts per million were then calculated using the voom [43] function in the limma package v. 3.40.6. Corrections for library generation batch were made using combat function in the sva package v. 3.32.1 [44].
Pairwise Comparison of Bacteria Species by Linear Modeling:
Log2-transformed and library generation batch corrected bacterial reads were then analyzed in three pairwise comparisons to identify bacteria species that were differentially abundant by transcriptional load based on smoking status. The three pairwise comparisons were SM vs. NS (SM/NS), SM vs. EC users (SM/EC) and EC users vs. NS (EC/NS). The limma [45] function contrasts.fit was employed for pairwise comparisons of smoking groups. Empirical bayes (eBayes) was applied to results from contrasts.fit to calculate log2 fold change and p-values using a moderated t-statistic. TopTable was applied to the results from eBayes and p-values were FDR-corrected [46]. Altered bacteria species with FDR-corrected P<0.1 were considered to be significant.
Ethics approval and consent to participate
This study was approved by the Ohio State University (OSU) Comprehensive Cancer Center Clinical Scientific Research Committee and the OSU Institutional Review Board (the IRB approval number: 2015C0088, ClinicalTrials.gov: NCT02596685) with written informed consent obtained from participants and was conducted in accordance with the U.S. Common Rule.
Data Availability Statement
The data generated in this study are publicly available in Gene Expression Omnibus (GEO) GSE180785.
Results
Bacterial Transcript Results:
Metatranscriptome data was collected for 28 BAL samples and 26 saliva samples. Each sample was sequenced to a minimum of 35 million total reads (microbial and human reads). In the 28 BAL samples, at least 78,000 sequenced reads mapped to 3,073 bacteria species, and in the 26 saliva samples, at least 17 million sequenced reads mapped to 3,345 bacteria species (Supplemental Table 1). Quality (e.g. possible outliers, batch effects) of the metatranscriptome data was evaluated using principal component analysis (See Supplemental Figure 1 for a detailed data analysis workflow). Accordingly, one outlier sample from a smoking subject was removed, and data were corrected for observed batch effects caused by library generation (Supplemental Figure 2 and Supplemental Figure 3).
Lung dysbiosis was not found based on SM, EC use or NS:
Analysis of the lung microbiome began with overall bacterial composition using both alpha diversity (number of observed species and evenness of abundance within subjects) and beta diversity (measured dissimilarity of bacterial communities between groups). The alpha diversity metrics analyzed included the Shannon H-Index (showing the similarity for the number of microbes and relative abundance were similar) (Figure 1A), the number of observed species (Supplemental Figure 4A) and the Gini-Simpson Index (which measures possible dominance of bacteria species in a given sample) (Supplemental Figure 4B).The Bray-Curtis dissimilarity index (which measures differences in bacteria composition using the quantitative bacterial counts, instead of presence or absence of bacteria), was used to assess beta diversity and no statistical differences were identified amongst the groups. When we plotted the Bray-Curtis dissimilarity index on a multi-dimensional scaling (MDS) plot, EC users and NS tended to cluster together compared to SM (Figure 1B).
Figure 1.

Lung Microbiome associated with Smoking Status. A) Distribution of alpha diversity, measured by the Shannon Diversity H-Index, in the samples stratified by smoking group; smoking groups were similar (P>0.05, Kruskal-Wallis) B) MDS plot clustered samples using Bray-Curtis dissimilarity index as a distance metric to compare beta diversity by smoking status (blue – never-smoker, green – e-cig users, red – smokers); never-smokers and e-cig users clustered together, compared to smokers. C) The relative abundances of bacteria species with at least 1% abundance in any smoking group identified in the lung. Bacteria species colored in red were species with > 1% abundance in both the lung and oral microbiome. D) Number of significant bacteria species in common from the multiple pairwise smoking status comparisons. There were 10 bacterial species in common between SM vs. NS and SM vs. EC. E) Volcano plot, of log2 fold change vs –log2(P-value), for SM vs. NS, SM vs. EC and EC vs. NS. Significant bacteria species were colored red. (FDR-adjusted p-value <0.1). Most of the bacteria species were decreased in SM vs. NS, while all bacteria species were decreased in SM vs. EC.
Differential abundance for the lung metatranscriptome:
Three pairwise differential analyses (SM/NS, SM/EC and EC/NS) were conducted to identify bacteria species with differentially abundant transcriptional loads. Figure 1C shows the highly abundant bacteria species in the lung, which was defined as bacteria species which were present with >1% abundance in the lung of any smoking subject. None of these species, however, were differentially abundant species that were identified between groups. There were 44 bacteria species with differentially abundant transcriptional loads when comparing SM/NS, 12 bacteria species for the SM/EC comparisons and none for the EC/NS comparison (FDR-adjusted P<0.1) (Supplemental Table 2). Ten bacteria species were identified in both SM/NS and SM/EC comparison (Figure 1D). Almost all of the differentially abundant bacteria in the SM/NS comparison, and all of the SM/EC comparisons, represented species which were significantly decreased in smokers (Figure 1E, Supplemental Table 2). Of the top 5 decreased species, Neisseria elongate, Neisseria sicca, Haemophilus parainfluenzae, which were identified in both SM/NS and SM/EC, while Fusobacterium periodonticum and Leptotrichia sp. oral taxon 212 were identified in SM/NS, and Neisseria zoodegmatis and Ottowia sp. oral taxon 894 were identified in SM/EC comparison; N. zoodegmatis and O. sp. oral taxon 894 were also decreased in the SM/NS comparisons, but were not in the top 5 decreased species (Figure 2, Table 2). Neisseria sp. KEM232 and Curvibacter sp. AEP1–3 were two bacteria species identified in only the SM/EC comparison (Figure 2A). There were 8 bacterial species that increased in the SM/NS comparisons, which were Niastella koreensis, Polaribacter sp. SA4–12, Myroides odoratimimus, Vibrio tasmaniensis, Paraburkholderia rhizoxinica, Stigmatella aurantiaca, Lactobacillus kefiranofaciens, and Paraburkholderia terrae (Figure 2B,2C).
Figure 2.

Relative abundances of significant bacteria from SM/NS and SM/Ecig pairwise comparisons. A) Aerobic bacteria species’ relative abundances were decreased in SM compared to EC users and NS. B) Aerobic bacteria species’ relative abundances were increased in SM compared to NS. C) Anaerobic bacteria species’ relative abundance in SM compared to EC users and NS. The first 3 bacteria species have decreased relative abundance in SM while the last 2 bacteria species have increased relative abundance in SM.
Table 2.
Top 5 Significant Bacteria Species by Absolute Fold Change from Pairwise Smoking Comparisons in the Lung and Oral Microbiome
| Smoking Comparisons | Bacteria Species | Log2 Fold Change | Raw P-value | FDR-adjusted P-value | |
|---|---|---|---|---|---|
| Lung | SM vs. NS | Neisseria elongata | −3.64 | 8.88E-06 | 6.93E-03 |
| Fusobacterium periodonticum | −3.55 | 4.56E-05 | 9.26E-03 | ||
| Haemophilus parainfluenzae | −3.55 | 3.27E-05 | 8.32E-03 | ||
| Neisseria sicca | −3.26 | 2.69E-05 | 8.32E-03 | ||
| Leptotrichia sp. oral taxon 212 | −3.06 | 1.44E-04 | 2.37E-02 | ||
| SM vs. EC | Neisseria elongata | −4.02 | 1.87E-06 | 1.42E-03 | |
| Neisseria sicca | −3.8 | 2.80E-06 | 1.42E-03 | ||
| Haemophilus parainfluenzae | −3.16 | 1.44E-04 | 2.43E-02 | ||
| Neisseria zoodegmatis | −2.88 | 1.13E-04 | 2.30E-02 | ||
| Ottowia sp. oral taxon 894 | −2.64 | 1.09E-05 | 3.71E-03 | ||
| Oral | SM vs. NS | Lactobacillus gasseri | 7.17 | 5.27E-04 | 1.72E-02 |
| Lactobacillus fermentum | 7.08 | 2.06E-04 | 1.35E-02 | ||
| Streptococcus lutetiensis | 6.01 | 4.81E-05 | 1.35E-02 | ||
| Lactobacillus crispatus | 5.83 | 1.45E-03 | 2.64E-02 | ||
| Lactobacillus helveticus | 5.79 | 5.78E-04 | 1.76E-02 | ||
| SM vs. EC | Herbaspirillum sp. Meg3 | −6.37 | 8.84E-05 | 3.44E-02 | |
| Candidatus Kinetoplastibacterium | −5.67 | 3.16E-04 | 3.44E-02 | ||
| desouzaii | |||||
| Neisseria sicca | −5.1 | 2.18E-04 | 3.44E-02 | ||
| Neisseria meningitidis | −4.45 | 1.20E-04 | 3.44E-02 |
Oral dysbiosis was only observed for beta diversity:
The alpha diversity measured by the Shannon H-index for assessing variance within a sample (number and relative abundances of the microbes) within groups indicated that each group of subjects were similar (Figure 3A). Similar results were found for the number of microbes (Supplemental Figure 4C) and by the Gini-Simpson Index (Supplemental Figure 4D). The beta diversity measured by Bray-Curtis dissimilarity index (which used quantitative bacterial counts to measure differences in bacteria composition), among the three groups were statistically different (PERMANOVA P<0.05). We observed in the MDS plot of Bray-Curtis dissimilarity index that NS and EC users tended to cluster together compared to the SM (Figure 3B).
Figure 3.

Oral microbes associated with smoking status. A) Distribution of alpha diversity, measured by the Shannon Diversity H-Index, in the samples stratified by smoking group; smoking groups were similar (P>0.05, Kruskal-Wallis) B) MDS plot clustered samples using Bray-Curtis dissimilarity index as a distance metric to compare beta diversity by smoking status (blue – never-smoker, green – e-cig users, red – smokers) never-smokers and e-cig users clustered together, compared to smokers. C) The relative abundances of bacteria species with at least 1% abundance in any smoking group in the oral microbiome are depicted. Bacteria species colored in red are those with > 1% abundance in both the lung and oral samples. D) Significant bacteria species in common from the multiple pairwise smoking status comparisons. E) Volcano plot, of log2 fold change vs –log2(P-value), for SM vs. NS, SM vs. EC and EC vs. NS. Significant bacteria species are colored red (FDR-adjusted p-value <0.1). F) Relative abundances of commensal oral microbiome species (Neisseria elongata, Haemophilus parainfluenzae and Fusobacterium periodonticum) by smoking groups. These common oral microbiome commensal species were all decreased in smokers.
Oral metatranscriptome for differential microbial abundance:
Figure 3C shows the 28 bacterial species identified in the oral cavity with >1% abundance. There were 152 bacteria species that were statistically significantly different for the SM/NS comparison (Figure 3D). 83 were increased and 69 were decreased in smokers (Figure 3E; Supplemental Table 2). Only 17 were found for the SM/EC comparisons, and all but 3 were decreased. Common oral microbiome species such as Haemophilus parainfluenzae, Prevotella melaninogenica, Ottowia sp. oral taxon 894, Campylobacter concisus, and Neisseria elongata were observed as decreased in the SM oral microbiome compared to EC users’ oral microbiome (Supplemental Table 2). The top 5 species that were identified in the oral microbiome comparison of SM/NS were Lactobacillus gasseri, Lactobacillus fermentum, Streptococcus lutetiensis, Lactobacillus crispatus, and Lactobacillus helveticus, all of which were increased in SM (Table 2). In SM/EC the top 5 species were, Herbaspirillum sp. Meg3, Candidatus Kinetoplastibacterium desouzaii, Neisseria sicca, Neisseria meningitidis, and Neisseria gonorrhoeae which were all decreased in SM (Table 2). Examples of bacteria species with altered transcriptional loads which were also observed to be differentially abundant in the lung microbiome include Neisseria elongata, Haemophilus parainfluenzae, and Fusobacterium periodonticum (Figure 3F). Notably, no oral bacteria species were found to be different when comparing EC/NS.
Comparison of oral and lung bacteria communities:
Combining SM/EC/NS, there were only 4 bacterial species found in both the lung and oral cavity with >1% abundance (Figure 1C; Figure 3C). These species were Haemophilus parainfluenzae, Prevotella melaninogenica, Prevotella jejuni and Haemophilus influenza which overlapped with the 28 highly abundant bacteria species in the oral microbiome. These species were found in a higher proportion of reads in the saliva samples (>5% abundance) compared to the lung samples (<5% abundance). The most abundant phyla were Proteobacteria, Firmicutes, Actinobacteria and Bacteroidetes (N=5) mostly overlap for the lung and oral cavity, except for Tenericutes in the lung and Fusobacteria in the oral cavity (Supplemental Figure 5 A,B). There was less concordance between the lung and oral cavity when analyzed for most abundant genera (N=10) (Supplemental Figure 5C,D) and species (N=10) (Supplemental Figure 6).
For the pairwise comparisons between the SM, EC users and NS showing differential abundance, Figures 4A and 4B show the number of non-overlapping and overlapping species observed in the oral cavity and lung in SM/NS and SM/EC comparison, respectively. 21 overlapping species were observed for the SM/NS comparisons (Supplemental Table 3), and for these 20 were decreased in both the lung and oral cavities. There was little overlap among the various groups (Supplemental Figure 7). Only 4 bacteria species were identified across all comparisons in the lung and oral cavity (Neisseria elongata, Neisseria sicca, Neisseria zoodegmatis, and Snodgrassella alvi). Heat maps were generated using the differentially abundant bacteria species of the lung and oral cavity microbiomes, as shown in Figures 4C and 4D. Smokers clustered together in one cluster in the lung, however in the oral microbiome the same clustering was not observed.
Figure 4.

Differences in Significant Bacteria Species of the Oral and Lung Microbiome. A-B) Upset plots show the number of bacteria species observed in oral microbiome, lung microbiome and both the oral and lung microbiome by pairwise smoking comparison. A) In the SM/NS pairwise comparison, 131 species were observed in the oral microbiome, 23 species observed in the lung microbiome, and 21 species were observed both the lung and oral microbiome. B) In the SM/EC pairwise comparison, 13 species were observed in the oral microbiome, 8 species were observed in the lung microbiome, and 4 species were observed in both the lung and oral microbiome. C-D) Heatmap generated from all significant microbes from pairwise comparison. C) Significant lung microbes were used to produce the heatmap, demonstrating clustering of all SM together in one group, with 2 EC users and 1 NS. D) Significant oral microbes do not cluster the smokers together in one group.
Discussion
This observational study was designed to compare the lung and oral microbiome population comparing SM, EC users and NS using metatranscriptomics. This study was the first to study the lung microbiome among EC users. The overall bacteria composition across the three study groups were similar in the lung (alpha and beta diversity), whereas differences were observed in the beta diversity in the oral microbiome. In the lung pairwise comparisons, the greatest difference in bacterial species abundance was between SM/NS, and almost all of the differences for SM/EC overlapped with the SM/NS comparisons. There were no differences between EC/NS, despite most of the EC users being former smokers. For comparisons of both the SM/NS and SM/EC users, almost all, or all, of the bacterial species were decreased in SM. Comparing the lung and oral microbiomes, many of the same bacterial species were present in both, but the overall profiles of the lung and oral microbiomes were different.
Prior studies of healthy participants have identified the presence of a core pulmonary microbiome [25, 47, 48]. Candidate genera present in at least 50% of subjects included Pseudomonas, Streptococcus, Prevotella, Fusobacterium, Haemophilus, Veillonella, and Porphyromonas. In this study, 15 bacterial species had >1% abundance. These core bacteria included Pseudomonas, Streptococcus, Prevotella, and Haemophilus, but not Veillonella, Porphyromonas or Fusobacterium.
Lung dysbiosis by smoking status has previously been studied for SM/NS by sequencing the 16S rRNA bacterial subunit (16S sequencing) rather than metatranscriptomics [25, 47, 49]. Metatranscriptomics analysis like 16S sequencing identified no differences for lung alpha or beta diversity. However, the three studies observed no differences in the lung microbiome between SM and NS. This result may be due to resolution limitations in 16S sequencing which studied higher order classifications of bacteria.
In this study, 44 lung bacterial species were differentially abundant when comparing SM/NS, and 12 bacteria species were differentially abundant when comparing SM/EC (FDR-adjusted P<0.1). Of those, 80% and 100% of the bacteria species abundances were decreased in SM respectively. The bacteria species with decreased transcriptional load among smokers were predominately gram-negative bacteria in the phyla Proteobacteria and Bacteroidetes. This negative association could be due to the toxic effects of smoking cigarettes on the lung which may include change in pH, humidity, heat, salivary flow, or xenobiotic degradation. There were 8 differentially abundant bacterial species that increased in SM compared to NS. These included bacteria species with unclear pathogenic relevance to lung disease or cancer pathways, although Myroides odoratimimus is a rare opportunistic pathogen in humans [50] and the Vibrio genus may cause foodborne infections [51].
There were negligible differences in the lung microbiome associated with EC use; no significant differences in transcriptional load were observed in comparisons of EC users with NS. In the SM/EC comparisons, all but two of the differentially abundant bacteria overlapped with the SM/NS comparisons, and thus these two may be a residual smoking effect. The two bacteria that were differentially abundant only in the SM/EC comparisons were Neisseria sp. KEM232 and Curvibacter sp. AEP1–3, both of which were decreased. The former is an oral organism that was isolated from dental caries [52]. The latter is identified as an aerobic bacteria species of unclear clinical significance. Overall, these data do not support the hypothesis that smoking-related lung disease or cancer is mediated by a specific bacterial agent, however the disease risk by microbiome is unknown at this time. Although the decrease in bacterial content may hypothetically enable an environment for pathogenic bacteria, none was seen in this study.
Oral microbiome bacterial diversity for SM/NS comparisons as found herein has been previously studied using 16S sequencing in 6 studies, and the results have generally indicated dysbiosis caused by smoking [25, 32, 53–56], although one study observed no dysbiosis [56]. In a large study, Wu et al. [54] observed increases in SM for the Actinobacteria phylum and Coriobacteriia class, and the genera Lactobacillus and Streptococcus. They also reported decreases in Proteobacteria phylum which included the genera Haemophilus and Neisseria, although not part of Proteobacteria phylum, the genus Capnocytophaga was also decreased in SM. Morris et al. [25] studied 64 participants and found differences only for Porphyromonas, Neisseria, and Gemella. Using metatranscriptomics, we found 152 bacterial species for the SM/NS comparisons, and confirmed the above study results for increased Lactobacillus and Streptococcus, and decreased Haemophilus, Neisseria, and Capnocytophaga genera. The increased genera in the oral microbiome were mostly anaerobic bacteria, implying that oxygen availability may have a role in bacterial populations’ response to smoking in the oral microbiome. The increase in Lactobacillus and Streptococcus genera also implied that smoking may select for gram positive bacteria.
Three prior studies have assessed associations of EC use with differences in the oral microbiome in humans [31, 32, 56]. While we observed no differentially abundant bacterial species for the EC/NS comparisons, Pushalkar et al [32], with 119 participants, reported an increased relative abundance for EC use compared to NS. They further identified 5 bacteria genera that were increased in EC users over SM, including Actinomyces and Campylobacter, and 5 bacteria genera that were decreased. In addition, Gansean et al. [31], studied gingival plaques with metatranscriptomic sequencing in 70 participants. The authors observed that EC use was associated with higher levels of gram-negative facultative anaerobes including Aggregatibacter, Haemophilus, and Rothia compared to NS [31]. Although their sequencing and sampling methods differed, both studies found EC use was associated with increase in the bacteria genera Leptotrichia, Selenomonas and Veillonella. Similar to our own findings, Stewart et al [56] reported no between-group differences in a study of 30 participants. It is possible that the reason we failed to observe a significant difference in our study may be due to the small sample size which resulted in limited statistical power to observe small differences.
Considering bacteria present in >1% in any subject, only 4 species were found in both the lung and oral microbiome. There were 21 bacterial species that were differentially abundant in the SM/NS comparisons in both the oral cavity and the lung, of which 20 were decreased in SM. Examples included Neisseria elongata, Neisseria sicca, Fusobacterium periodonticum and Haemophilus parainfluenza. Meanwhile, Lactobacillus kefiranofaciens was the only bacteria species with increased transcriptional load in both the lung and oral microbiome of SM/NS. Thus, while the lung microbiome may derive from oral microbiome via microaspiration and dispersion along the mucosa [26–28], this was not observed herein. Therefore, assessing the oral cavity as a surrogate for the lung microbiome is not supported by this study.
There were several limitations in our study. This was a small study with a mostly male study population in smokers, so generalizability to smoking and EC user populations will need to be affirmed in additional studies. Second, because of this study’s cross-sectional design which evaluated the metatranscriptome at a single time-point, these results may not accurately reflect the dynamic nature of microbial populations and their transcriptional activity, which we assume vary over time and length of exposure to EC use or smoking combustible cigarettes. Additionally, the study design and small sample size makes the results susceptible to confounding such as seasonality, air pollution and occupational exposures, which would need to be explored in a larger study. However, we believe that the effects of these potential confounders would be low compared to the direct inhalation and lung effects of smoking and vaping. Also, there were more male white SM than the NS and EC groups, which could be a source of bias. However, in our other studies for gene expression and other ‘omics biomarkers, we did not find that race and gender were confounders. Larger studies would be needed to explore this potential confounding. Another limitation is the possibility that the bronchoscope traveling through the nasopharynx or oropharynx may get contaminated with upper airway bacteria affecting BAL results. Given that the differentially abundant bacteria had little overlap lessens this concern, and other studies that have examined this found little evidence for contamination by upper airway bacteria [28, 57–59]. In this study, we did not examine the amount of cigarette smoking or EC use given the small number of study subjects, but should be considered in larger studies. Last, the oral microbiome results may be confounded by the presence of periodontal disease, which was not assessed herein [31, 32].
Conclusions
Lung microbiome dysbiosis may be associated with lung disease including lung cancer, and dysbiotic lung microbiome populated by oral species have been observed to drive lung cancer progression [60]. In this study, the hypothesis that the pathogenesis for smoking-related lung disease or cancer includes a toxic effect on the lung microbiome was not supported because of the similar bacterial diversity for SM and NS, and because most differentially abundant bacteria are either decreased, or have an unclear clinical significance. No pathogenic bacteria were identified which may have overgrown due to decreases in other bacteria. The lung microbiome for EC users was similar to NS, which indicated that EC use does not have a strong pathogenetic effect on the lung mediated by the microbiome. Our results for the oral microbiome in particular the SM/NS and SM/EC comparisons were consistent with prior studies. However, when the oral and lung microbiome are compared, the former does not appear to be a surrogate biospecimen for assessing smoking and EC effects on the lung microbiome. Given the small study size, the results should be considered hypothesis-generating and replicated in larger studies.
Supplementary Material
Acknowledgements
The authors acknowledge the support of the OSU Comprehensive Cancer Center Genomics Shared Resource, Bioinformatics Shared Resource and the Biostatistics Shared Resource. The authors also thank the study participants, the staff and nurses of the OSU Clinical Research Center, and Sahar Kamel for assisting in recruiting participants.
Funding
Research reported in this publication was supported by funding from the National Cancer Institute (P30 CA016058) awarded to P.G. Shields, the FDA Center for Tobacco Products (CTP; P50CA180908 and R21HL147401) both awarded to P.G. Shields, the National Center for Advancing Translational Sciences (UL1TR001070), Pelotonia Intramural Research Funds awarded to M-A. Song, and the Prevent Cancer Foundation awarded to P.G. Shields. This work was supported in part by the Intramural/Extramural research program of the National Center for Advancing Translational Sciences, National Institutes of Health.
Footnotes
Conflicts of interest
P.G. Shields has provided expert testimony for law firms representing plaintiffs in tobacco litigation. No potential conflicts of interest were disclosed by the other authors.
Reference
- 1.Services, U.D.o.H.a.H., The Health Consequences of Smoking-50 years of Progress: A Report of the Surgeon General, ed. U.D.o.H.a.H. Services. 2014, Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. [Google Scholar]
- 2.Goniewicz ML, Miller CR, Sutanto E, and Li D, How effective are electronic cigarettes for reducing respiratory and cardiovascular risk in smokers? A systematic review. Harm Reduct J, 2020. 17(1): p. 91. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Leslie FM, Unique, long-term effects of nicotine on adolescent brain. Pharmacol Biochem Behav, 2020. 197: p. 173010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Akiyama Y and Sherwood N, Systematic review of biomarker findings from clinical studies of electronic cigarettes and heated tobacco products. Toxicol Rep, 2021. 8: p. 282–294. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Marczylo T, How bad are e-cigarettes? What can we learn from animal exposure models? J Physiol, 2020. 598(22): p. 5073–5089. [DOI] [PubMed] [Google Scholar]
- 6.Keith R and Bhatnagar A, Cardiorespiratory and Immunologic Effects of Electronic Cigarettes. Curr Addict Rep, 2021: p. 1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Shields PG, Berman M, Brasky TM, Freudenheim JL, Mathe E, McElroy JP, et al. , A Review of Pulmonary Toxicity of Electronic Cigarettes in the Context of Smoking: A Focus on Inflammation. Cancer Epidemiol Biomarkers Prev, 2017. 26(8): p. 1175–1191. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA, and Knight R, The microbiome and human cancer. Science, 2021. 371(6536). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.González-Sánchez P and DeNicola GM, The microbiome(s) and cancer: know thy neighbor(s). J Pathol, 2021. Jul;254(4):332–343. [DOI] [PubMed] [Google Scholar]
- 10.Goto T, Airway Microbiota as a Modulator of Lung Cancer. Int J Mol Sci, 2020. 21(9). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Liu NN, Ma Q, Ge Y, Yi CX, Wei LQ, Tan JC, et al. , Microbiome dysbiosis in lung cancer: from composition to therapy. NPJ Precis Oncol, 2020. 4(1): p. 33. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Hosgood HD, Cai Q, Hua X, Long J, Shi J, Wan Y, et al. , Variation in oral microbiome is associated with future risk of lung cancer among never-smokers. Thorax, 2021. 76(3): p. 256–263. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Yang J, Mu X, Wang Y, Zhu D, Zhang J, Liang C, et al. , Dysbiosis of the Salivary Microbiome Is Associated With Non-smoking Female Lung Cancer and Correlated With Immunocytochemistry Markers. Front Oncol, 2018. 8: p. 520. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Wang YJ, Wu SS, Chu J, and Kong XY, Lung microbiome mediates the progression from chronic obstructive pulmonary disease to lung cancer through inflammation. Yi Chuan, 2021. 43(1): p. 30–39. [DOI] [PubMed] [Google Scholar]
- 15.Martins D, Mendes F, and Schmitt F, Microbiome: A Supportive or a Leading Actor in Lung Cancer? Pathobiology, 2021. 88(2): p. 198–207. [DOI] [PubMed] [Google Scholar]
- 16.Paudel KR, Dharwal V, Patel VK, Galvao I, Wadhwa R, Malyla V, et al. , Role of Lung Microbiome in Innate Immune Response Associated With Chronic Lung Diseases. Front Med (Lausanne), 2020. 7: p. 554. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Mendez R, Banerjee S, Bhattacharya SK, and Banerjee S, Lung inflammation and disease: A perspective on microbial homeostasis and metabolism. IUBMB Life, 2019. 71(2): p. 152–165. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Huang C and Shi G, Smoking and microbiome in oral, airway, gut and some systemic diseases. J Transl Med, 2019. 17(1): p. 225. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Mason MR, Preshaw PM, Nagaraja HN, Dabdoub SM, Rahman A, and Kumar PS, The subgingival microbiome of clinically healthy current and never smokers. ISME J, 2015. 9(1): p. 268–72. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Shah SA, Ganesan SM, Varadharaj S, Dabdoub SM, Walters JD, and Kumar PS, The making of a miscreant: tobacco smoke and the creation of pathogen-rich biofilms. NPJ Biofilms Microbiomes, 2017. 3: p. 26. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Delima SL, McBride RK, Preshaw PM, Heasman PA, and Kumar PS, Response of subgingival bacteria to smoking cessation. J Clin Microbiol, 2010. 48(7): p. 2344–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Fullmer SC, Preshaw PM, Heasman PA, and Kumar PS, Smoking cessation alters subgingival microbial recolonization. J Dent Res, 2009. 88(6): p. 524–8. [DOI] [PubMed] [Google Scholar]
- 23.Mammen MJ, Scannapieco FA, and Sethi S, Oral-lung microbiome interactions in lung diseases. Periodontol 2000, 2020. 83(1): p. 234–241. [DOI] [PubMed] [Google Scholar]
- 24.Dickson RP and Huffnagle GB, The Lung Microbiome: New Principles for Respiratory Bacteriology in Health and Disease. PLoS Pathog, 2015. 11(7): p. e1004923. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Morris A, Beck JM, Schloss PD, Campbell TB, Crothers K, Curtis JL, et al. , Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med, 2013. 187(10): p. 1067–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Venkataraman A, Bassis CM, Beck JM, Young VB, Curtis JL, Huffnagle GB, et al. , Application of a neutral community model to assess structuring of the human lung microbiome. mBio, 2015. 6(1). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Segal LN, Clemente JC, Tsay JC, Koralov SB, Keller BC, Wu BG, et al. , Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype. Nat Microbiol, 2016. 1: p. 16031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Falkowski NR, Huffnagle GB, et al. , Bacterial Topography of the Healthy Human Lower Respiratory Tract. mBio, 2017. 8(1). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Holliday R, Chaffee BW, Jakubovics NS, Kist R, and Preshaw PM, Electronic Cigarettes and Oral Health. J Dent Res, 2021: p. 220345211002116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Yang I, Sandeep S, and Rodriguez J, The oral health impact of electronic cigarette use: a systematic review. Crit Rev Toxicol, 2020. 50(2): p. 97–127. [DOI] [PubMed] [Google Scholar]
- 31.Ganesan SM, Dabdoub SM, Nagaraja HN, Scott ML, Pamulapati S, Berman ML, et al. , Adverse effects of electronic cigarettes on the disease-naive oral microbiome. Sci Adv, 2020. 6(22): p. eaaz0108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Pushalkar S, Paul B, Li Q, Yang J, Vasconcelos R, Makwana S, et al. , Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection. iScience, 2020. 23(3): p. 100884. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Yang M, Cousineau A, Liu X, Luo Y, Sun D, Li S, et al. , Direct Metatranscriptome RNA-seq and Multiplex RT-PCR Amplicon Sequencing on Nanopore MinION - Promising Strategies for Multiplex Identification of Viable Pathogens in Food. Front Microbiol, 2020. 11: p. 514. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Song MA, Freudenheim JL, Brasky TM, Mathe EA, McElroy JP, Nickerson QA, et al. , Biomarkers of Exposure and Effect in the Lungs of Smokers, Nonsmokers, and Electronic Cigarette Users. Cancer Epidemiol Biomarkers Prev, 2020. 29(2): p. 443–451. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Centers for Disease Control and Prevention [Internet]. Adult Tobacco Use Information; c2017 [cited 2021 April 20]; Available from: https://www.cdc.gov/nchs/nhis/tobacco/tobacco_glossary.htm.
- 36.Martin M, Cutadapt Removes Adapter Sequences from High-Throughput Sequencing Reads. EMBnet Journal, 2011(17): p. 10–12. [Google Scholar]
- 37.Trapnell C, Pachter L, and Salzberg SL, TopHat: discovering splice junctions with RNA-Seq. Bioinformatics, 2009. 25(9): p. 1105–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Wood DE, and Salzberg SL, Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol, 2014. 15(3): p. R46. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Lu J, Breitwieser FP, Thielen P, and Salzberg SL, Bracken: estimating species abundance in metagenomics data. Peerj Computer Science, 2017(1), [e104]. [Google Scholar]
- 40.Lahti L and Shetty S, microbiome R package. Version 1.10.0 [software]. 2019. Oct 15: [cited 2020 Jan 8]. Available from:http://microbiome.github.io.
- 41.Oksanen J, Guillaume Blanchet F, Friendly M, Kindt R, Legendre P, McGlinn D, et al. , vegan: Community Ecology Package. Version 2.5–7 [software]. 2020. Jan 8 [cited 2020 Feb 10] Available from: https://CRAN.R-project.org/package=vegan.
- 42.Robinson MD, McCarthy DJ, and Smyth GK, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 2010. 26(1): p. 139–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Law CW, Chen Y, Shi W, and Smyth GK, voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol, 2014. 15(2): p. R29. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Leek JT, Johnson WE, Parker HS, Jaffe AE, and Storey JD, The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics, 2012. 28(6): p. 882–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. , limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 2015. 43(7): p. e47. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Benjamini Y and Hochberg Y, Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological), 1995. 57(1): p. 289–300. [Google Scholar]
- 47.Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, Schmidt LA, et al. , Analysis of the lung microbiome in the “healthy” smoker and in COPD. PLoS One, 2011. 6(2): p. e16384. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. , Disordered microbial communities in asthmatic airways. PLoS One, 2010. 5(1): p. e8578. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Einarsson GG, Comer DM, McIlreavey L, Parkhill J, Ennis M, Tunney MM, et al. , Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers. Thorax, 2016. 71(9): p. 795–803. [DOI] [PubMed] [Google Scholar]
- 50.Lorenzin G, Piccinelli G, Carlassara L, Scolari F, Caccuri F, Caruso A, et al. , Myroides odoratimimus urinary tract infection in an immunocompromised patient: an emerging multidrug-resistant micro-organism. Antimicrob Resist Infect Control, 2018. 7: p. 96. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Baker-Austin C, Oliver JD, Alam M, Ali A, Waldor MK, Qadri F, et al. , Vibrio spp. infections. Nat Rev Dis Primers, 2018. 4(1): p. 8. [DOI] [PubMed] [Google Scholar]
- 52.El Houmami N, Durand GA, Bzdrenga J, Darmon A, Minodier P, Seligmann H, et al. , A New Highly Sensitive and Specific Real-Time PCR Assay Targeting the Malate Dehydrogenase Gene of Kingella kingae and Application to 201 Pediatric Clinical Specimens. J Clin Microbiol, 2018. 56(8). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Sato N, Kakuta M, Hasegawa T, Yamaguchi R, Uchino E, Kobayashi W, et al. , Metagenomic analysis of bacterial species in tongue microbiome of current and never smokers. NPJ Biofilms Microbiomes, 2020. 6(1): p. 11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Wu J, Peters BA, Dominianni C, Zhang Y, Pei Z, Yang L, et al. , Cigarette smoking and the oral microbiome in a large study of American adults. ISME J, 2016. 10(10): p. 2435–46. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Kumar PS, Matthews CR, Joshi V, de Jager M, and Aspiras M, Tobacco smoking affects bacterial acquisition and colonization in oral biofilms. Infect Immun, 2011. 79(11): p. 4730–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Stewart CJ, Auchtung TA, Ajami NJ, Velasquez K, Smith DP, De La Garza R, et al. , Effects of tobacco smoke and electronic cigarette vapor exposure on the oral and gut microbiota in humans: a pilot study. PeerJ, 2018. 6: p. e4693. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Dickson RP, Erb-Downward JR, Freeman CM, Walker N, Scales BS, Beck JM, et al. , Changes in the lung microbiome following lung transplantation include the emergence of two distinct Pseudomonas species with distinct clinical associations. PLoS One, 2014. 9(5): p. e97214. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Bassis CM, Erb-Downward JR, Dickson RP, Freeman CM, Schmidt TM, Young VB, et al. , Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio, 2015. 6(2): p. e00037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Beck JM, Huffnagle GB, et al. , Spatial Variation in the Healthy Human Lung Microbiome and the Adapted Island Model of Lung Biogeography. Ann Am Thorac Soc, 2015. 12(6): p. 821–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Tsay JJ, Wu BG, Sulaiman I, Gershner K, Schluger R, Li Y, et al. , Lower Airway Dysbiosis Affects Lung Cancer Progression. Cancer Discov, 2021. 11(2): p. 293–307. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data generated in this study are publicly available in Gene Expression Omnibus (GEO) GSE180785.
